Tenax Therapeutics (TENX) EBIT: 2010-2016
Historic EBIT for Tenax Therapeutics (TENX) over the last 3 years, with Dec 2016 value amounting to -$42.2 million.
- Tenax Therapeutics' EBIT fell 248.87% to -$42.2 million in Q4 2016 from the same period last year, while for Dec 2016 it was -$64.5 million, marking a year-over-year increase of 27.03%. This contributed to the annual value of -$19.5 million for FY2024, which is 136.75% down from last year.
- As of Q4 2016, Tenax Therapeutics' EBIT stood at -$42.2 million, which was down 838.22% from -$4.5 million recorded in Q3 2016.
- In the past 5 years, Tenax Therapeutics' EBIT registered a high of -$682,843 during Q4 2012, and its lowest value of -$74.1 million during Q2 2013.
- For the 2-year period, Tenax Therapeutics' EBIT averaged around -$16.1 million, with its median value being -$8.9 million (2015).
- In the last 5 years, Tenax Therapeutics' EBIT soared by 66.76% in 2012 and then tumbled by 3,873.03% in 2013.
- Quarterly analysis of 4 years shows Tenax Therapeutics' EBIT stood at -$682,843 in 2012, then plummeted by 3,873.03% to -$74.1 million in 2013, then reached -$12.1 million in 2015, then tumbled by 248.87% to -$42.2 million in 2016.
- Its EBIT was -$42.2 million in Q4 2016, compared to -$4.5 million in Q3 2016 and -$5.7 million in Q2 2016.